TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Clinical Results After Frozen-thawed Healthy Blastocyst Transfer in Natural Cycle Versus Cycle With Endometrial Preparation
Brief Summary: This study evaluates the difference in pregnancy rate transferring a healthy blastocyst in natural or artificial cycle.


Options:
A: Arm Label: Estrogen pre-treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: 17beta-estradiol | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: 17beta-estradiol; Assigned to Arm(s): Estrogen pre-treatment
B: Arm Label: OCP; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levonorgestrel and ethinylestradiol | Arm Label: Oral estradiol valerate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Estradiol valerate | Intervention Type: DRUG; Name: Levonorgestrel and ethinylestradiol; Assigned to Arm(s): OCP | Intervention Type: DRUG; Name: Estradiol valerate; Assigned to Arm(s): Oral estradiol valerate
C: Arm Label: natural cycle; Type: OTHER; Interventions: Other: embryo transfer | Arm Label: hormonal cycle; Type: ACTIVE_COMPARATOR; Interventions: Other: embryo transfer | Intervention Type: OTHER; Name: embryo transfer; Assigned to Arm(s): hormonal cycle, natural cycle
D: Arm Label: 150 µg Corifollitropin Alfa; Type: EXPERIMENTAL; Interventions: Drug: Corifollitropin alfa, Drug: Placebo RecFSH / follitropin beta, Biological: RecFSH / Follitropin beta (Days 8 to hCG), Drug: Ganirelix, Biological: hCG, Biological: Progesterone | Arm Label: 200 IU recFSH; Type: ACTIVE_COMPARATOR; Interventions: Biological: RecFSH / Follitropin beta (Days 1 to 7), Drug: Placebo Corifollitropin alfa, Biological: RecFSH / Follitropin beta (Days 8 to hCG), Drug: Ganirelix, Biological: hCG, Biological: Progesterone | Intervention Type: DRUG; Name: Corifollitropin alfa; Assigned to Arm(s): 150 µg Corifollitropin Alfa | Intervention Type: BIOLOGICAL; Name: RecFSH / Follitropin beta (Days 1 to 7); Assigned to Arm(s): 200 IU recFSH | Intervention Type: DRUG; Name: Placebo Corifollitropin alfa; Assigned to Arm(s): 200 IU recFSH | Intervention Type: DRUG; Name: Placebo RecFSH / follitropin beta; Assigned to Arm(s): 150 µg Corifollitropin Alfa | Intervention Type: BIOLOGICAL; Name: RecFSH / Follitropin beta (Days 8 to hCG); Assigned to Arm(s): 150 µg Corifollitropin Alfa, 200 IU recFSH | Intervention Type: DRUG; Name: Ganirelix; Assigned to Arm(s): 150 µg Corifollitropin Alfa, 200 IU recFSH | Intervention Type: BIOLOGICAL; Name: hCG; Assigned to Arm(s): 150 µg Corifollitropin Alfa, 200 IU recFSH | Intervention Type: BIOLOGICAL; Name: Progesterone; Assigned to Arm(s): 150 µg Corifollitropin Alfa, 200 IU recFSH

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of a Tailored Virtual Intervention as an Instrument of Prevention and Support to Improve the Health of PLHIV and Reduce Comorbidity Associated With HIV (MP-02-2015-5853)
Brief Summary: The purpose of this study is to evaluate the efficacy of a web-based tailored intervention to support persons living with HIV (PLHIV) manage the demands inherent to their health condition, particularly as regards to the adoption of health behaviours such as being physically active, following a healthy diet and quitting smoking.

This randomized controlled trial is currently conducted entirely online at www.lhivehealthy.ca


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Telemedicine Smoking Cessation Program | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telephone Quitline Smoking Cessation Program | Intervention Type: BEHAVIORAL; Name: Telemedicine Smoking Cessation Program; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Telephone Quitline Smoking Cessation Program; Assigned to Arm(s): 2
B: Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A
D: Arm Label: Website A; Type: EXPERIMENTAL; Interventions: Behavioral: Website A | Arm Label: Website B; Type: OTHER; Interventions: Other: Website B | Intervention Type: BEHAVIORAL; Name: Website A; Assigned to Arm(s): Website A | Intervention Type: OTHER; Name: Website B; Assigned to Arm(s): Website B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis
Brief Summary: The primary objective of the study is to assess the clinical efficacy of repeat subcutaneous (SC) doses of dupilumab, compared with placebo, to relieve symptoms in adult participants with active, moderate to severe Eosinophilic Esophagitis (EoE).

The secondary objectives of the study are:

* To assess the safety, tolerability, and immunogenicity of SC doses of dupilumab in adult participants with active, moderate to severe EoE
* To assess the effect of dupilumab on esophageal eosinophilic infiltration
* To evaluate the pharmacokinetics (PK) of dupilumab in adult participants with EoE


Options:
A: Arm Label: IV ABT-308 in asthmatics; Type: EXPERIMENTAL; Interventions: Drug: ABT-308, Drug: Placebo | Arm Label: SC ABT-308 in asthmatics; Type: EXPERIMENTAL; Interventions: Drug: ABT-308, Drug: Placebo | Arm Label: IV ABT-308 in healthy volunteers; Type: EXPERIMENTAL; Interventions: Drug: ABT-308, Drug: Placebo | Intervention Type: DRUG; Name: ABT-308; Assigned to Arm(s): IV ABT-308 in asthmatics, IV ABT-308 in healthy volunteers | Intervention Type: DRUG; Name: ABT-308; Assigned to Arm(s): SC ABT-308 in asthmatics | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): IV ABT-308 in asthmatics, IV ABT-308 in healthy volunteers | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): SC ABT-308 in asthmatics
B: Arm Label: Dupilumab 300 mg QW; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 300 mg QW | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Oral Budesonide Suspension (OBS); Type: EXPERIMENTAL; Interventions: Drug: Oral Budesonide Suspension (OBS) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Oral Budesonide Suspension (OBS); Assigned to Arm(s): Oral Budesonide Suspension (OBS) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: omalizumab; Type: EXPERIMENTAL; Interventions: Drug: omalizumab | Intervention Type: DRUG; Name: omalizumab; Assigned to Arm(s): omalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cooperation for Improved Pharmacotherapy in Home-dwelling Elderly People Receiving Polypharmacy - The COOP Study
Brief Summary: Polypharmacy increases the risk of adverse drug effects, interactions and other drug-related problems, and several studies indicate that inappropriate drug use is a major reason for poor health and impaired function in the elderly. A majority of interventions for improvement of drug treatment in the elderly have been evaluated by the use of surrogate outcomes such as drug-related problems, number of prescribed drugs or prevalence of potentially inappropriate prescriptions - and it is so far unclear whether such interventions can result in clinical significant improvements. The primary objective of this trial is therefore to evaluate the effect upon patients, relatives and local health care service of a structured cooperation between a hospital-based geriatrician and family physicians on complex drug regimens in home-dwelling frail elderly patients.


Options:
A: Arm Label: Patient Group 1; Type: EXPERIMENTAL; Interventions: Other: Health TAPESTRY Intervention | Arm Label: Patient Group 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Health TAPESTRY Intervention; Assigned to Arm(s): Patient Group 1 | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Patient Group 2
B: Intervention Type: BEHAVIORAL; Name: Geriatric Resources for Assessment & Care of Elders (GRACE); Assigned to Arm(s): N/A
C: Arm Label: Comprehensive drug review; Type: EXPERIMENTAL; Interventions: Other: Comprehensive drug review | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Comprehensive drug review; Assigned to Arm(s): Comprehensive drug review
D: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: Mobile Geriatric Team intervention | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Mobile Geriatric Team intervention; Assigned to Arm(s): Intervention group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cooperation for Improved Pharmacotherapy in Home-dwelling Elderly People Receiving Polypharmacy - The COOP Study
Brief Summary: Polypharmacy increases the risk of adverse drug effects, interactions and other drug-related problems, and several studies indicate that inappropriate drug use is a major reason for poor health and impaired function in the elderly. A majority of interventions for improvement of drug treatment in the elderly have been evaluated by the use of surrogate outcomes such as drug-related problems, number of prescribed drugs or prevalence of potentially inappropriate prescriptions - and it is so far unclear whether such interventions can result in clinical significant improvements. The primary objective of this trial is therefore to evaluate the effect upon patients, relatives and local health care service of a structured cooperation between a hospital-based geriatrician and family physicians on complex drug regimens in home-dwelling frail elderly patients.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Computer-Assisted Decision Support | Intervention Type: PROCEDURE; Name: Computer-Assisted Decision Support; Assigned to Arm(s): 2
B: Intervention Type: BEHAVIORAL; Name: Opinion leader generated and endorsed evidence summaries; Assigned to Arm(s): N/A
C: Arm Label: Before collarborative pharmaceutical care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: After collarborative pharmaceutical care; Type: EXPERIMENTAL; Interventions: Other: Collaborative Pharmaceutical Care | Intervention Type: OTHER; Name: Collaborative Pharmaceutical Care; Assigned to Arm(s): After collarborative pharmaceutical care
D: Arm Label: Comprehensive drug review; Type: EXPERIMENTAL; Interventions: Other: Comprehensive drug review | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Comprehensive drug review; Assigned to Arm(s): Comprehensive drug review

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cooperation for Improved Pharmacotherapy in Home-dwelling Elderly People Receiving Polypharmacy - The COOP Study
Brief Summary: Polypharmacy increases the risk of adverse drug effects, interactions and other drug-related problems, and several studies indicate that inappropriate drug use is a major reason for poor health and impaired function in the elderly. A majority of interventions for improvement of drug treatment in the elderly have been evaluated by the use of surrogate outcomes such as drug-related problems, number of prescribed drugs or prevalence of potentially inappropriate prescriptions - and it is so far unclear whether such interventions can result in clinical significant improvements. The primary objective of this trial is therefore to evaluate the effect upon patients, relatives and local health care service of a structured cooperation between a hospital-based geriatrician and family physicians on complex drug regimens in home-dwelling frail elderly patients.


Options:
A: Arm Label: Intervention; Type: OTHER; Interventions: Other: E-learning | Arm Label: Control; Type: OTHER; Interventions: Other: E-learning | Intervention Type: OTHER; Name: E-learning; Assigned to Arm(s): Control, Intervention
B: Arm Label: Pharmacist Intervention; Type: EXPERIMENTAL; Interventions: Procedure: Pharmacist Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Pharmacist Intervention; Assigned to Arm(s): Pharmacist Intervention
C: Arm Label: naive Deprescribing arm; Type: EXPERIMENTAL; Interventions: Other: Team-care deprescribing with deprescribing guide | Arm Label: naive Wait-list Control arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: non-naive Deprescribing arm; Type: EXPERIMENTAL; Interventions: Other: Team-care deprescribing with deprescribing guide | Arm Label: non-naive Wait-list Control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Team-care deprescribing with deprescribing guide; Assigned to Arm(s): naive Deprescribing arm, non-naive Deprescribing arm
D: Arm Label: Comprehensive drug review; Type: EXPERIMENTAL; Interventions: Other: Comprehensive drug review | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Comprehensive drug review; Assigned to Arm(s): Comprehensive drug review

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Home-based or Center-based Aerobic Exercise on Physical Function, Nutritional Status Ans Cardiopulmonary Parameters in Patients With Chronic Kidney Disease
Brief Summary: Patients will be randomly assigned to perform the training program in center or home-based . The training program will be conducted in accordance with the recommendations of the American College of Sports Medicine. All training sessions will be preceded by stretching of large muscle groups and heating (5 minutes) and at the end by cool down and stretching (5 minutes). The program will consist of 24 weeks with three sessions per week on alternate days. The aerobic training will be continuous, with an increment of 10 minutes in duration every 4 weeks. The intensity will be prescribed according to ventilatory threshold, characterized by the highest intensity of physical exertion fully maintained by aerobic energy pathways. The intensity control was done by means of the heart rate value obtained at ventilatory threshold.

Both groups receive the same intervention. However, a group exercise held in the center on a treadmill with the direct supervision of a physical education teacher. The other group will exercise at home with telephone follow-up weekly and once a month will be held at the training center under the supervision of a physical education teacher.

It will also constituted a control group remain without performing any activity during the study period. After 24 weeks patients receive the same advice the team conducting the training at home.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Other: Exercise | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise
B: Arm Label: Usual Care (UC); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Social Cognitive Theory (SCT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Social Cognitive Theory | Arm Label: Monitoring; Type: ACTIVE_COMPARATOR; Interventions: Other: Monitoring | Arm Label: Combined; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Social Cognitive Theory, Other: Monitoring | Intervention Type: BEHAVIORAL; Name: Social Cognitive Theory; Assigned to Arm(s): Combined, Social Cognitive Theory (SCT) | Intervention Type: OTHER; Name: Monitoring; Assigned to Arm(s): Combined, Monitoring
C: Arm Label: sedentary control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Home-based aerobic exercise; Type: EXPERIMENTAL; Interventions: Other: Aerobic exercise | Arm Label: Center-based aerobic exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: Aerobic exercise | Intervention Type: OTHER; Name: Aerobic exercise; Assigned to Arm(s): Center-based aerobic exercise, Home-based aerobic exercise
D: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: weight reduction; Type: EXPERIMENTAL; Interventions: Behavioral: weight reduction | Intervention Type: BEHAVIORAL; Name: weight reduction; Assigned to Arm(s): weight reduction

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Analgesic Efficacy of Preoperative Oral Administration of Dexketoprofen Trometamol in Third Molar Surgery, Compared to Postoperative Administration
Brief Summary: The purpose of the present investigation is to evaluate the effectiveness of the preoperative administration of Dexketoprofen Trometamol, employing the third molar surgery model, when compared to postoperative administration of the same drug. It was hypothesized that preoperative oral Dexketoprofen trometamol will reduce the intensity of pain by 30% after 8 hours of the surgery, when compared with post-operative administration.


Options:
A: Arm Label: Group ETORICOXIB PREOP; Type: EXPERIMENTAL; Interventions: Drug: Etoricoxib, Drug: Placebo | Arm Label: Group ETORICOXIB POSTOP; Type: EXPERIMENTAL; Interventions: Drug: Etoricoxib, Drug: Placebo | Arm Label: Group PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Etoricoxib; Assigned to Arm(s): Group ETORICOXIB POSTOP, Group ETORICOXIB PREOP | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group ETORICOXIB POSTOP, Group ETORICOXIB PREOP, Group PLACEBO
B: Arm Label: Treatment A:; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paracetamol (1g x 4), Drug: Ibuprofen (400 mg x 4) | Arm Label: Treatment B:; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paracetamol (1g x 4), Drug: Placebo (x4) | Arm Label: Treatment C:; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ibuprofen (400 mg x 4), Drug: Placebo (x4) | Arm Label: Treatment D:; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paracetamol (0,5 g x 4), Drug: Ibuprofen (200 mg x 4) | Intervention Type: DRUG; Name: Paracetamol (1g x 4); Assigned to Arm(s): Treatment A:, Treatment B: | Intervention Type: DRUG; Name: Ibuprofen (400 mg x 4); Assigned to Arm(s): Treatment A:, Treatment C: | Intervention Type: DRUG; Name: Paracetamol (0,5 g x 4); Assigned to Arm(s): Treatment D: | Intervention Type: DRUG; Name: Ibuprofen (200 mg x 4); Assigned to Arm(s): Treatment D: | Intervention Type: DRUG; Name: Placebo (x4); Assigned to Arm(s): Treatment B:, Treatment C:
C: Arm Label: Preemptive; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etoricoxibe | Arm Label: Postoperative; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Etoricoxibe; Assigned to Arm(s): Preemptive | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Postoperative
D: Arm Label: Dexketoprofen trometamol; Type: EXPERIMENTAL; Interventions: Drug: Dexketoprofen trometamol | Arm Label: Preoperative control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Preoperative control | Intervention Type: DRUG; Name: Dexketoprofen trometamol; Assigned to Arm(s): Dexketoprofen trometamol | Intervention Type: DRUG; Name: Preoperative control; Assigned to Arm(s): Preoperative control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Control Trial of Magnetic Resonance Imaging-targeted Biopsy Compared to Standard Trans-rectal Ultrasound Guided Biopsy for the Diagnosis of Prostate Cancer in Men Without Prior Biopsy
Brief Summary: This evaluates the detection rates of prostate cancer by MRI-targeted prostate biopsy compared to standard 12-core trans-rectal ultrasound guided (TRUS) prostate biopsy. Each participant will be randomly allocated to one of the biopsy tests.

We hypothesise that MRI-targeted biopsy will detect no fewer clinically significant cancers than TRUS biopsy but will detect fewer clinically insignificant prostate cancers than TRUS biopsy.


Options:
A: Arm Label: Prostate biopsy; Type: OTHER; Interventions: Procedure: Prostate biopsy | Intervention Type: PROCEDURE; Name: Prostate biopsy; Assigned to Arm(s): Prostate biopsy
B: Arm Label: MRI-arm; Type: EXPERIMENTAL; Interventions: Device: MRI, Procedure: MRI-targeted biopsy | Arm Label: TRUS-biopsy arm; Type: ACTIVE_COMPARATOR; Interventions: Procedure: TRUS-biopsy | Intervention Type: DEVICE; Name: MRI; Assigned to Arm(s): MRI-arm | Intervention Type: PROCEDURE; Name: MRI-targeted biopsy; Assigned to Arm(s): MRI-arm | Intervention Type: PROCEDURE; Name: TRUS-biopsy; Assigned to Arm(s): TRUS-biopsy arm
C: Intervention Type: OTHER; Name: biologic sample preservation procedure; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: study of socioeconomic and demographic variables; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: diffusion-weighted magnetic resonance imaging; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: dynamic contrast-enhanced magnetic resonance imaging; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: multiparametric magnetic resonance imaging; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: transperineal prostate biopsy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: transrectal prostate biopsy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: ultrasound-guided prostate biopsy; Assigned to Arm(s): N/A
D: Intervention Type: PROCEDURE; Name: Prostate HistoScanning; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Multi-parametric MRI; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Transperineal prostate mapping biopsy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Image guided biopsies; Assigned to Arm(s): N/A

Answer: B